MARKET

GOVXW

GOVXW

Geovax Labs Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7203
-0.0494
-6.42%
Closed 16:00 08/11 EDT
OPEN
0.7700
PREV CLOSE
0.7697
HIGH
0.9498
LOW
0.7185
VOLUME
15.58K
TURNOVER
9.38K
52 WEEK HIGH
2.980
52 WEEK LOW
0.1501
MARKET CAP
--
P/E (TTM)
-0.2394
1D
5D
1M
3M
1Y
5Y
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update
Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology co...
GlobeNewswire · 08/03 20:00
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of a peer-revi...
GlobeNewswire · 07/28 13:00
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious...
GlobeNewswire · 07/26 13:00
Atlanta company GeoVax raises more money for Covid-19 vaccine, cancer treatment trials
The $20 million will be used to accelerate three ongoing clinical trials by the company for Covid-19 vaccines and cancer treatments. In January, GeoVax raised $10 million for the same clinical trials.
American City Business Journals · 07/08 18:34
BRIEF-Geovax Labs Files Prospectus Relates To Resale Of Up To 21.4 Million Shares By Selling Stockholders - SEC Filing
reuters.com · 06/14 20:44
GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development
Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer i...
GlobeNewswire · 06/13 13:00
GeoVax to Present at BIO International Convention 2022
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing...
GlobeNewswire · 06/07 13:00
BRIEF-Geovax Announces $20 Million Registered Direct And PIPE Offerings
reuters.com · 05/25 17:50
More
No Data
Learn about the latest financial forecast of GOVXW. Analyze the recent business situations of Geovax Labs Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-1.72-1.29-0.86-0.43
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.11%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Dodd
Chief Financial Officer/Secretary
Mark Reynolds
Chief Scientific Officer
Mark Newman
Chief Scientific Officer
Harriet Robinson
Other
Kelly Mckee
Independent Director
Randal Chase
Independent Director
Dean Kollintzas
Independent Director
Robert McNally
Independent Director
John Spencer
No Data
No Data
About GOVXW
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.

Webull offers kinds of Geovax Labs Inc stock information, including NASDAQ:GOVXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOVXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOVXW stock methods without spending real money on the virtual paper trading platform.